2004, Number 2
<< Back
Rev Mex Cardiol 2004; 15 (2)
Usefulness of lercanidipine in patients with essential arterial hypertension
Lepe ML, Hernández SI, Granados AJ, López BA
Language: Spanish
References: 28
Page: 75-82
PDF size: 99.31 Kb.
ABSTRACT
Objective: To evaluate the usefulness and tolerability of a recent generation of calcium antagonist (lercanidipine) on blood pressure,
and on the treatment of adult patients with a diagnosis of mild to moderate arterial hypertension.
Methodology: In an cuasi-experimental
and multicentric clinical study developed in the Mexican Republic, among September 2003 and April 2003, 773 patients with a clinical diagnosis of arterial hypertension were enrolled. Every patient received lercanidipine 10 mg once-a-day. Each subject in the study was his own control, when they were evaluated before and after the administration of the treatment.
Follow-up was done during a-three-months period through a personal interview, a questionnaire response, and a clinical evaluation on each visit. Data capture and proceedings were done through the EpiInfo 2000
program and the uni and bi-variant analysis with the SPSS v.10 statistics package.
Results: From the total of evaluable patients, 580 had moderate
hypertension and 193 mild hypertension. Since the first visit and without an important variation in the heart frequency, 93.7% of all of these patients had a favorable response to lercanidipine with a reduction of both, the diastolic and systolic pressures. Adverse reactions were mild and were present in 11.4% of the patients; those were headache, facial redness and malleolar edema.
Conclusions: In patients with mild to moderate arterial hypertension, and/or
with a previous bad response to any initial therapy, the administration of lercanidipine 10 mg per day, decreased blood pressure to normal values in a short period of time, with few adverse reactions of mild intensity.
REFERENCES
Klag MI, Wheiton PK. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-8.
Loyd-Iones DM, Evans JC. Differential impact of systolic and diastolic blood pressure level on JNC-VI staging. Joint National Committee on prevention, detection, evaluation and treatment of High blood pressure. Hypertension 1999; 34: 381-5.
Eastern Stroke and Coronary Heart Disease Collaborative Research Group Blood Pressure, cholesterol and stroke in eastern Asia. Lancet 1998; 352: 1801-7.
Hansson L, Lindholm LH. Randomized trial of old and new hypertensive drugs in elderly patients; cardiovascular mortality and morbidity in the swedish trial in old patients with hypertension. 2 study. Lancet 1999; 354: 1751-6.
Ninci MA, Magliocca R. Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double blind study. J Cardiovasc Pharmacol 1997; 29: S40-44.
Cafiero M, Giasi M. Long term (12 months) treatment with lercanidipine in patients with mild to moderate hypertension. J Cardiovas Pharmacol 1997; 29(suppl 2): 1-30.
Benetos A, Waeber B. Influence of age, risk factors and cardiovascular and renal disease on arterial stiffness: Clinical applications. IPC center and INSERM U258 (AB), Paris, France 2000.
Benetos A, Rudnichi A. Influence of heart rate on mortality in a french population role of age, gender and blood pressure. Hypertension 1999; 33: 44-52.
Aubert L, Bovet P. Knowledge, attitudes and practices on hypertension in a country in epidemiological transition. Hypertension 1999; 31: 1136-45.
Lorenzo C, Serrano-Rios M. Prevalence of hypertension in hispanic and non-hispanic white populations. Hypertension 2002; 39: 203.
Charchar F, Tomaszewski M. The Y chromosome effect on blood pressure in two european populations. Hypertension 2002; 39: 353.
Lang T, Gaudemaris R. Prevalence and therapeutic control of hypertension in 30,000 subjects in the workplace. Hypertension 2001; 38: 449.
Banegas J, Rodríguez-Artalejo F. Blood pressure in Spain. Hypertension 1998; 32: 998-1002.
Primatesta P, Falaschetti E. Association between smoking and blood pressure: Evidence from the Health Survey for England. Hypertension 2001; 37: 187.
Fuchs FD, Chamless LE. Alcohol consumption and the incidence of hypertension: The atherosclerosis risk in communities study. Hypertension 2001; 37: 1242.
Brown M, Castaigne A. Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension 2000; 35: 1038.
Burt V, Cutler J. Trends in prevalence, awareness, treatment and control of hypertension in the adult US population. Hypertension 1995; 26: 60-9.
Cushman W, Materson B. Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial. Hypertension 2001; 38: 953.
Gu D, Reynolds K. Prevalence, awareness, treatment and control of hypertension in China. Hypertension 2002; 10: 116-22.
Leonetti G, Magnani B. Tolerability of long term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15: 932-40.
McClellan KJ, Jarvis B. Lercanidipine: A review of its use in hypertension. Drugs 2000; 60(5): 1123-40.
Barrios V, Navarro A. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Blood Press 2002; 11: 95-100.
Acanfora A, Trojano L. A randomized, double-blind comparison of 10 and 20 mg lercanidipine in patients with stable effort angina: Effects on myocardial ischemia and heart rate variability. Am J Ther 2002; 9: 444-53.
Viviani GL. Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension. J Cardiovasc Pharmacol 2002; 40: 133-9.
Borghi C, Dormi A. Improved Tolerability of the Dihydropyridine Calcium-Channel Antagonist Lercanidipine: The Lercanidipine Challenge Trial. Blood Pressure 2003; 12 (Suppl 1): 1-8.
Epstein M. Lercanidipine: A novel dihydropyridine calcium-channel blocker. Heart Dis 2001; 3: 398-407.
Brown MJ, Castaigne A. Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension 2000; 35: 1038-42.
Agarwal R. Treatment of hypertension in patients with diabetes: Lessons from recent trials. Cardiol Rev 2001; 9: 36-44.
Full text